Wong GLH, et al. - A territory-wide cohort of chronic hepatitis B (CHB) patients who received entecavir (ETV) and/or tenofovir disoproxil fumarate (TDF) in 2005-2016 was identified to determine the impact of normal on-treatment alanine aminotransferase (ALT) during antiviral treatment with ETV or TDF in patients with CHB. For this investigation, serial on-treatment ALT levels were collected and analyzed. They excluded patients with hepatic events before or during the first year of antiviral treatment or follow-up <1 year. Results of this study suggested that normal on-treatment ALT can be translated into improved clinical outcomes in CHB patients receiving nucleos(t)ide analogues {NA} treatment.